273 results on '"Evrard, Alexandre"'
Search Results
2. Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patients
3. Partitioning dysprosium's electronic spin to reveal entanglement in non-classical states
4. Probing chiral edge dynamics and bulk topology of a synthetic Hall system
5. Probing quantum criticality and symmetry breaking at the microscopic level
6. Enhanced magnetic sensitivity with non-gaussian quantum fluctuations
7. Quantum-enhanced sensing using non-classical spin states of a highly magnetic atom
8. Anisotropic light-shift and magic-polarization of the intercombination line of Dysprosium atoms in a far-detuned dipole trap
9. La pharmacogénétique en oncologie, ce qu’il faut savoir à l’officine
10. Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug–drug interactions with oral targeted therapy
11. Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen
12. Toxicity and pharmacokinetic profile of SGM-101, a fluorescent anti-CEA chimeric antibody for fluorescence imaging of tumors in patients
13. Association inhabituelle d’inhibiteurs de BRAF et de MEK : réponse clinique d’un mélanome métastatique traité par dabrafénib–cobimétinib
14. Cancer genomics guide clinical practice in personalized medicine
15. La génétique somatique des tumeurs solides, un incontournable à l’ère de la médecine de précision
16. Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report
17. Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer
18. Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients
19. Regorafenib (REGO) plus FOLFIRINOX as frontline treatment in patients (pts) with RAS-mutated metastatic colorectal cancer (mCRC): A phase I/II, dose-escalation and dose-expansion study.
20. An automated quantitative image analysis tool for the identification of microtubule patterns in plants
21. Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key.
22. Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects
23. The promoter of the wheat puroindoline-a gene (PinA) exhibits a more complex pattern of activity than that of the PinB gene and is induced by wounding and pathogen attack in rice
24. Abstract P5-13-23: Pharmacokinetic determinants of palbociclib hematological toxicity
25. Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis
26. Partitioning dysprosium's electronic spin to reveal entanglement in nonclassical states
27. PXR Modulates the Prostate Cancer Cell Response to Afatinib by Regulating the Expression of the Monocarboxylate Transporter SLC16A1
28. Liquid chromatography–tandem mass spectrometric assay for the quantification of CDK4/6 inhibitors in human plasma in a clinical context of drug-drug interaction
29. Salmonella enterica Flagellin Is Recognized via FLS2 and Activates PAMP-Triggered Immunity in Arabidopsis thaliana
30. Therapeutic Bayesian monitoring of sunitinib in two patients with impaired absorption or elimination
31. Promoter analysis and immunolocalisation show that puroindoline genes are exclusively expressed in starchy endosperm cells of wheat grain
32. Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency
33. Abstract PS5-16: Impact of drug-drug interaction on palbociclib serum levels: Interest of therapeutic drug monitoring
34. Severe or lethal toxicities with nucleosidic analogs: time for action
35. CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations
36. Model‐Based Quantification of Impact of Genetic Polymorphisms and Co‐Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer
37. Vancomycin Serum Concentration after 48 h of Administration: A 3-Years Survey in an Intensive Care Unit
38. Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
39. The Anti-Cancer Drug Dabrafenib Is a Potent Activator of the Human Pregnane X Receptor
40. Probing chiral edge dynamics and bulk topology of a synthetic Hall system
41. Pharmacogenetics and pharmacokinetics modeling of unexpected and extremely severe toxicities after sorafenib intake
42. GENE EXPRESSION PROFILING IN HEAD AND NECK SQUAMOUS CELL CARCINOMA: CLINICAL PERSPECTIVES
43. Enhanced magnetic sensitivity with non-gaussian quantum fluctuations
44. O6-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C
45. 5-fluorouracil therapeutic drug monitoring Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer
46. Probing Quantum Criticality and Symmetry Breaking at the Microscopic Level
47. Enhanced Magnetic Sensitivity with Non-Gaussian Quantum Fluctuations
48. Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study
49. A common polymorphism in NR1H2 (LXRbeta) is associated with preeclampsia
50. Pregnane × Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.